Citations 2
Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Liu, Jacklyn , Takahashi, Yoko , Rehman, Umar , Turri-Zanoni, Mario, Mattavelli, Davide, Counsell, Nicholas , Ferrari, Marco, Rampinelli, Vittorio , Vermi, William , Lombardi, Davide , Saade, Rami , Park, Ki Wan , Emanuel, Oscar , Schartinger, Volker Hans , Franchi, Alessandro , Facco, Carla, Sessa, Fausto, Battocchio, Simonetta , Eriksen, Patrick René Gerhard , Haddouchi, Mohamed El, Maragliano, Roberta , Lelkaitis, Giedrius , Saraswathula, Anirudh, KAUR, RAMAN PREET, Mydlarz, Wojciech K. , Ishii, Masaru, Dave, Manas, Fenton, Tim R. , Lim, Alison E. , Okhovat, Saleh , Elegio, Gyleen, Pouvreau, Pierre, Thariat, Juliette, Digue, L., Ferrand, François-Régis, Costes-Martineau, Valerie, Castain, Claire, Kermadec, H. De , O’Neill, James Paul, Lacy, Peter D., Vaz, Francis, O’Flynn, Paul, Howard, David J., Stimpson, Paul, Wang, S, Royle, Gary , Steele, Christopher, Jay, A., Carnell, Dawn , Forster, Martin D., Thomson, David, Buchwald, Christian von, Lllorente, Jose Luis, Hermsen, Mario A., Jurmeister, Philipp , Capper, David, Gallia, Gary L. , Js, Tay, Mohyeldin, Ahmed, Fernandez-Miranda, Juan, LE, Q, West, Robert B., Patel, Z M, Hwang, P H, Facchetti, Fabio , Nicolai, Piero, Ferrarotto, Renata, Phan, Jack, Bossi, P., Castelnuovo, P., Moya-Plana, Antoine, Verillaud, B., Garnis, Cathie , Thamboo, Andrew , Olawuni, Felicia O., Moore, E.J., Choby, Garret M., Lal, Devyani, Akhave, Neal S. , Bell, Diana , Su, Shirley Y., Lund, Valerie J., London, Nyall R. , HANNA, Ehab, Lechner, Matt, Hwang, Peter H. , Thariat, Juliette , Phan, Jack , Le, Quynh‐Thu , Patel, Zara M. , Franchi, Alessandro , Su, Shirley Y. , Lund, Valerie J. , Lechner, Matt , Castelnuovo, Paolo , Ferrari, Marco , Turri‐Zanoni, Mario , Mattavelli, Davide , Moya‐Plana, Antoine , Rehman, Umar , Turri-Zanoni, Mario , Mattavelli, Davide , Ferrari, Marco , Schartinger, Volker H , Maragliano, Roberta , Lelkaitis, Giedrius , Fenton, Tim R , Thariat, Juliette , Ferrand, Francois-Regis , Howard, David J , Carnell, Dawn , Forster, Martin D , von Buchwald, Christian , Hermsen, Mario , Tay, Joshua K , Le, Quynh-Thu , Patel, Zara , Hwang, Peter H , Facchetti, Fabio , Phan, Jack , Bossi, Paolo , Castelnuovo, Paolo , Moya-Plana, Antoine , Olawuni, Felicia, Su, Shirley Y , Lund, Valerie J , Lechner, Matt , Sessa, Fausto , Bendtsen, Simone K. , Jakobsen, Kathrine Kronberg , Saraswathula, Anirudh , Ramanathan, Murugappan , Ishii, Masaru, Dupin, Charles Louis , Digue, Laurence, Costes‐Martineau, Valérie , Castain, Claire , Hintze, Justin , O'Flynn, Paul E., Steele, Christopher D. , Woods, Robbie , Llorente Pendás, José Luis , Capper, David , Nayak, Jayakar V. , Nicolai, Piero , Vérillaud, Benjamin , Choby, Garret , Hanna, Ehab Y.
Cancers | January 26, 2026 | Volume: 18 | Issue: 3 | Pages: 366
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, Robert I. , Bischoff, Lindsay , Applewhite, Megan K. , Bernet, Victor , Blomain, Erik , Brito, Maria , Busaidy, Naifa L. , Campbell, Michael J. , DeLozier, Olivia M. , Duh, Quan‐Yang , Ehya, Hormoz, Grady, Erin C., Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Lorch, Jochen H. , Mandel, Susan J., Mydlarz, Wojciech K. , Raeburn, Christopher D., Rezaee, Rod , Ritter, Hadley E., Roth, Mara Y. , Salgado, Sarimar Agosto , Scheri, Randall P., Sipos, Jennifer A. , Wirth, Lori J. , Darlow, Susan, Cassara, Carly J., Sliker, Bailee , Haddad, Robert , Guo, Theresa , Haymart, Megan R. , Kotwal, Anupam , Markovina, Stephanie T. , Nabell, Lisle M. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Worden, Francis P. , Yeh, Michael W.
Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available
The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.